PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34302727-0 2021 Lenvatinib targets PDGFR-beta pericytes and inhibits synergy with thyroid carcinoma cells: novel translational insights. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 19-29 34302727-2 2021 Lenvatinib is a clinically available TK inhibitor (TKI) that targets PDGFR-beta. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 69-79 34302727-11 2021 Lenvatinib strongly inhibits pericyte viability by down-regulating MAPK, pAKT and p-p70S6-kinase downstream PDGFR-beta. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 108-118 34302727-12 2021 Critically, lenvatinib significantly induces higher BRAF WT/V600E-PTC cell death when co-cultured with pericytes, as a result of pericyte targeting via PDGFR-beta. lenvatinib 12-22 platelet derived growth factor receptor alpha Homo sapiens 152-162 30220234-2 2018 Lenvatinib, an orally active inhibitor of multiple receptor tyrosine kinases (VEGFR 1-3, FGFR 1-4, PDGFRa, RET and KIT), showed preclinical and clinical activity in the treatment of solid tumors, including HCC. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 99-105 32817132-1 2020 BACKGROUND: Lenvatinib inhibits tyrosine kinases, including vascular endothelial growth factor (VEGF) receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor alpha, RET proto-oncogene and KIT proto-oncogene, receptor tyrosine kinase. lenvatinib 12-22 platelet derived growth factor receptor alpha Homo sapiens 147-192 30685073-1 2019 Lenvatinib is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors 1-4, RET, KIT, and platelet-derived growth factor receptor-alpha. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 152-197 34428101-5 2021 Lenvatinib is a multitargeted tyrosine kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRalpha, RET, and KIT signaling networks implicated in tumor angiogenesis, approved in locally recurrent or metastatic, progressive, RAI-refractory DTC. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 78-88 33198671-3 2020 Therefore, lenvatinib (a known inhibitor of VEGF receptors 1-3, FGFRs 1-4, and PDGFR-alpha) was evaluated for second-line treatment of BTC. lenvatinib 11-21 platelet derived growth factor receptor alpha Homo sapiens 79-90 29656442-2 2018 In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial, HTN was the most frequent adverse event of lenvatinib, an inhibitor of VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet-derived growth factor receptor alpha (PDGFRalpha), ret proto-oncogene (RET), and stem cell factor receptor (KIT). lenvatinib 142-152 platelet derived growth factor receptor alpha Homo sapiens 260-305 29615459-4 2018 An association of KDR, KIT, and PDGFRA amplification with the sensitivity of thyroid cancer cells to lenvatinib was shown in vitro Three genetically distinct types of ATCs are proposed.Conclusions: This large-scale analysis describes genetic alterations in a cohort of thyroid cancers enriched in advanced cases. lenvatinib 101-111 platelet derived growth factor receptor alpha Homo sapiens 32-38 29656442-2 2018 In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial, HTN was the most frequent adverse event of lenvatinib, an inhibitor of VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet-derived growth factor receptor alpha (PDGFRalpha), ret proto-oncogene (RET), and stem cell factor receptor (KIT). lenvatinib 142-152 platelet derived growth factor receptor alpha Homo sapiens 307-317 30069768-1 2018 Lenvatinib is an oral receptor tyrosine kinase inhibitor (TKI) with activity against vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors (FGFR) 1-4, platelet-derived growth factor receptor-alpha (PDGFRalpha), and RET and KIT proto-oncogenes. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 189-234 29517103-1 2018 Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor (TKI) of VEGFR1-VEGFR3, FGFR1-FGFR4, PDGFRalpha, RET and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks involved in tumor angiogenesis. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 100-110 30032643-1 2018 Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRalpha), stem cell factor receptor (KIT), and rearranged during transfection (RET). lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 172-217 30032643-1 2018 Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRalpha), stem cell factor receptor (KIT), and rearranged during transfection (RET). lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 219-229 29468981-1 2018 BACKGROUND AND OBJECTIVE: Lenvatinib is an oral, multitargeted Tyrosine Kinase Inhibitor (TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR1-VEGFR3), fibroblast growth factor receptors (FGFR1-FGFR4), Platelet-Derived Growth Factor Receptor (PDGFR)alpha, rearranged during transfection (RET), and v-kit (KIT) signaling networks implicated in tumor angiogenesis. lenvatinib 26-36 platelet derived growth factor receptor alpha Homo sapiens 251-262 30069768-1 2018 Lenvatinib is an oral receptor tyrosine kinase inhibitor (TKI) with activity against vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors (FGFR) 1-4, platelet-derived growth factor receptor-alpha (PDGFRalpha), and RET and KIT proto-oncogenes. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 236-246 26867945-1 2016 Lenvatinib (Lenvima ) is an oral, multi-targeted tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, fibroblast growth factor receptors 1, 2, 3 and 4, platelet-derived growth factor receptor alpha, and RET and KIT signalling networks, which are implicated in tumour growth and maintenance. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 148-243 27817859-6 2016 Lenvatinib (Lenvima ) is a tyrosine kinase inhibitor (TKI) targeting the VEGFR1-3, FGFR 1-4, PDGFR-alpha, RET and c-kit. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 93-104 27799794-1 2016 Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular molecules involved in the modulation of angiogenesis and lymphangiogenesis: vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, and platelet-derived growth factor receptor alpha. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 222-310 26678514-6 2016 Lenvatinib targets vascular endothelial growth factor receptors 1-3 (VEGFR1-3), fibroblast growth factor receptors 1-4 (FGFR-1-4), RET, c-kit, and platelet-derived growth factor receptor alpha (PDGFRalpha). lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 147-192 26678514-6 2016 Lenvatinib targets vascular endothelial growth factor receptors 1-3 (VEGFR1-3), fibroblast growth factor receptors 1-4 (FGFR-1-4), RET, c-kit, and platelet-derived growth factor receptor alpha (PDGFRalpha). lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 194-204 25795101-1 2015 Lenvatinib (Lenvima ) is a multitargeted receptor kinase inhibitor that inhibits the kinase activities of vascular endothelial-derived growth factor receptors 1, 2 and 3, fibroblast growth factor receptors 1, 2, 3 and 4, platelet-derived growth factor receptor alpha, RET and KIT. lenvatinib 0-10 platelet derived growth factor receptor alpha Homo sapiens 171-266 25795101-1 2015 Lenvatinib (Lenvima ) is a multitargeted receptor kinase inhibitor that inhibits the kinase activities of vascular endothelial-derived growth factor receptors 1, 2 and 3, fibroblast growth factor receptors 1, 2, 3 and 4, platelet-derived growth factor receptor alpha, RET and KIT. lenvatinib 12-19 platelet derived growth factor receptor alpha Homo sapiens 171-266 26484847-1 2015 INTRODUCTION: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor of VEGFR1,2,3,4, FGFR1,2,3,4, PDGFR-alpha as well as RET and KIT signaling network. lenvatinib 14-24 platelet derived growth factor receptor alpha Homo sapiens 106-117 25295214-2 2014 Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1-3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1-4), platelet derived growth factor receptor alpha (PDGFRalpha), KIT, and RET. lenvatinib 21-31 platelet derived growth factor receptor alpha Homo sapiens 207-252 25295214-2 2014 Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1-3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1-4), platelet derived growth factor receptor alpha (PDGFRalpha), KIT, and RET. lenvatinib 21-31 platelet derived growth factor receptor alpha Homo sapiens 254-264 25197551-1 2014 BACKGROUND: Lenvatinib is an oral inhibitor of multiple receptor tyrosine kinases (RTKs) targeting vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet growth factor receptor alpha (PDGFR alpha), RET and KIT. lenvatinib 12-22 platelet derived growth factor receptor alpha Homo sapiens 239-250